Biologic agents in islet transplantation (Q38126884)

29 August 2017

Biologic agents in islet transplantation (English)

1 reference

29 August 2017

Boris Gala-Lopez

1

1 reference

29 August 2017

Andrew R Pepper

series ordinal

2

1 reference

29 August 2017

A M James Shapiro

series ordinal

3

1 reference

29 August 2017

1 October 2013

1 reference

29 August 2017

Current diabetes report

1 reference

29 August 2017

13

1 reference

29 August 2017

713-722

1 reference

29 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-013-0414-8

29 August 2017

0 references

cites work

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Immunosuppression: practice and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Induction immunosuppressive therapies in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

International trial of the Edmonton protocol for islet transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Five-year follow-up after clinical islet transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Biologics in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Assignment of quantities to biological medicines: an old problem re-discovered

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Standardization of biological medicines: the first hundred years, 1900-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Metrics for antibody therapeutics development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Which are the antibodies to watch in 2012?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Formulation and delivery issues for monoclonal antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Which are the antibodies to watch in 2013?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Preclinical and clinical safety of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Hazard identification and risk assessment for biologics targeting the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Rationale for using belatacept in combination with sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Biological agents in kidney transplantation: belatacept is entering the field

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Biological and biomaterial approaches for improved islet transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

State of the art of clinical islet transplantation and novel protocols of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

A personal perspective: 100-year history of the humoral theory of transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Strategic opportunities in clinical islet transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Tolerance-inducing strategies in islet transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Immunosuppressive drugs for kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Strategies for B-lymphocyte repertoire remodeling in transplantation tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

C1-inhibitor and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Successful management of a B-type cardiac allograft into an O-type man with 3(1/2)-year clinical follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Clinical islet transplant: current and future directions towards tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Advancing islet transplantation: from engraftment to the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Strategies toward single-donor islets of Langerhans transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0414-8

A centennial review; the 1890 tetanus antitoxin paper of von Behring and Kitasato and the related developments

21 January 2018

1 reference

12 December 2020

Repurification: rescue rather than routine remedy

1 reference

12 December 2020

Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation

1 reference

12 December 2020

Therapeutic in vivo use of the A1-CD3 monoclonal antibody

1 reference

12 December 2020

Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients

1 reference

12 December 2020

Induction of immunosuppression with polyclonal antithymocyte globulins: an overview.

1 reference

12 December 2020

Anti-inflammatory properties of exenatide in human pancreatic islets

1 reference

12 December 2020

Effect of tumor necrosis factor alpha and of the soluble tumor necrosis factor receptor on insulin secretion of isolated islets of Langerhans

1 reference

12 December 2020

Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes

1 reference

12 December 2020

A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy

1 reference

12 December 2020

B cells and transplantation tolerance

1 reference

12 December 2020

Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.

1 reference

12 December 2020

Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor

1 reference

12 December 2020

Unraveling the secrets of single donor success in islet transplantation

1 reference

12 December 2020

Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients

1 reference

12 December 2020

BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection

1 reference

12 December 2020

Improving efficacy of clinical islet transplantation with iodixanol-based islet purification, thymoglobulin induction, and blockage of IL-1β and TNF-α

1 reference

12 December 2020

Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation

1 reference

12 December 2020

Novel immunosuppressive agents in kidney transplantation.

1 reference

12 December 2020

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)

1 reference

12 December 2020

10.1007/S11892-013-0414-8

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference